Tags : Active Crohn’s Disease

Janssen Reports Results of Tremfya (guselkumab) in Interim Analysis of

Tuba Khan October 12, 2020

Shots: The P-II GALAXI 1 study involves assessing of Tremfya vs PBO in patients with mod. to severely active CD with intolerance to conventional therapies. In interim analyses, patients were […]readmore

Biosimilars Clinical Trials

Celltrion Reports Results of Remsima SC (biosimilar, infliximab) in a

Tuba Khan February 17, 2020

Shots: The clinical study involves assessing the PK, efficacy, and safety of CT-P13 SC vs CT-P13 IV in 131 patients with active CD & UC for 1yr. Following loading doses […]readmore

Tags : Active Crohn’s Disease

Janssen Reports Results of Tremfya (guselkumab) in Interim Analysis of

Celltrion Reports Results of Remsima SC (biosimilar, infliximab) in a

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Active Crohn’s Disease

Janssen Reports Results of Tremfya (guselkumab) in Interim Analysis of

Celltrion Reports Results of Remsima SC (biosimilar, infliximab) in a

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company